A subject was enrolled in a multicenter, double-blinded clinical trial of ofloxacin-containing multidrug therapy for leprosy by the World Health Organization in 1992 and she developed multiple physical symptoms a few hours after taking the regimen. Physical examination and laboratory work-ups could not support a medical diagnosis and she was eventually dropped from the study. Decoding revealed that she belonged in the control group given the World Health Organization/multiple drug therapy-multibacillary regimen. In the course of treatment, she was diagnosed with conversion disorder and was subsequently treated with an antipsychotic.
BT - Dermatologic clinics C1 - http://www.ncbi.nlm.nih.gov/pubmed/18346555?dopt=Abstract DA - 2008 Apr DO - 10.1016/j.det.2007.11.008 IS - 2 J2 - Dermatol Clin LA - eng N2 -A subject was enrolled in a multicenter, double-blinded clinical trial of ofloxacin-containing multidrug therapy for leprosy by the World Health Organization in 1992 and she developed multiple physical symptoms a few hours after taking the regimen. Physical examination and laboratory work-ups could not support a medical diagnosis and she was eventually dropped from the study. Decoding revealed that she belonged in the control group given the World Health Organization/multiple drug therapy-multibacillary regimen. In the course of treatment, she was diagnosed with conversion disorder and was subsequently treated with an antipsychotic.
PY - 2008 SP - 239 EP - 43 EP - vi T2 - Dermatologic clinics TI - Conversion disorder: "an adverse reaction" to watch out for. VL - 26 SN - 0733-8635 ER -